| Miss Kara Taylor, MA CCC-SLP | |
|
2765 Chapel Pl # 6004, Crestview Hills, KY 41017-3413 | |
| (859) 344-4511 | |
| Not Available |
| Full Name | Miss Kara Taylor |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 2765 Chapel Pl # 6004, Crestview Hills, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982183158 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Kara Taylor, MA CCC-SLP 6966 Zenith Ct, Liberty Twp, OH 45011-7207 Ph: (513) 939-4076 | Miss Kara Taylor, MA CCC-SLP 2765 Chapel Pl # 6004, Crestview Hills, KY 41017-3413 Ph: (859) 344-4511 |
News Archive
A specialized subpopulation of the antibody-producing B cells of the immune system plays a "double-barreled" role in triggering both kinds of immunity - innate and acquired, Duke University Medical Center immunologists have discovered.
Diabetes is becoming one of the major health problems in the European and US populations. It is frequently associated with overweight, hypertension and high serum cholesterol levels, representing a dangerous combination of risk factors for the development of heart and vascular diseases.
Glioblastoma is regarded as the most malignant form of brain tumor. In many cases, neurosurgeons are not able to remove such tumors completely because of the risk of destroying too much brain tissue in the process. Moreover, it is often impossible to identify all the fine extensions by which the tumor spreads into surrounding healthy tissue. To at least slow down the growth of tumor cells that have remained in the head, almost all glioblastoma patients are treated by radiotherapy after surgery.
RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.
› Verified 1 days ago
Crista Yeager, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2865 Chancellor Dr, Suite 105, Crestview Hills, KY 41017 Phone: 859-426-5666 | |
Ms. Stephanie Bright, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2865 Chancellor Dr Ste 105, Crestview Hills, KY 41017 Phone: 859-426-5666 | |
Lauren Elizabeth Ford, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2865 Chancellor Dr, Crestview Hills, KY 41017 Phone: 859-426-5666 | |
Janet Dea Hackett, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2865 Chancellor Dr, Suite 105, Crestview Hills, KY 41017 Phone: 859-426-5666 Fax: 859-426-5665 | |
Ms. Leigha Brooke Ochsner, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 330 Thomas More Pkwy Ste 102, Crestview Hills, KY 41017 Phone: 859-426-5666 | |
Mrs. Debra Lynn Way, ST Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2865 Chancellor Dr, Suite 105, Crestview Hills, KY 41017 Phone: 856-426-5666 Fax: 856-426-5665 | |
Ms. Jacqueline Sue Adams, ST Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2865 Chancellor Dr, Suite 105, Crestview Hills, KY 41017 Phone: 859-426-5666 Fax: 859-426-5665 |